Trials / Completed
CompletedNCT00613379
PRO 140 by IV Administration in Adults With HIV-1 Infection
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study of PRO 140 by Intravenous Administration in Adult Subjects With Human Immunodeficiency Virus Type 1 Infection
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- CytoDyn, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is: 1. To assess and characterize the PK and PD of PRO 140 administered IV 2. To assess the antiviral activity of PRO 140 3. To assess the safety and tolerability of PRO 140
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PRO 140 | 10 mg/kg PRO 140, one IV dose (N=10) |
| DRUG | PRO 140 | 5 mg/kg PRO 140, one IV dose (N=10) |
| DRUG | Placebo | PBO, one IV dose (N=10) |
Timeline
- Start date
- 2007-12-01
- Primary completion
- 2008-08-01
- Completion
- 2008-08-01
- First posted
- 2008-02-13
- Last updated
- 2016-07-15
- Results posted
- 2013-05-31
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00613379. Inclusion in this directory is not an endorsement.